Our science board is composed of:
James Abbruzzese, MD Chief, Medical Oncology Duke University
Markus Büchler, MD Chairman, Surgery Heidelberg University, Germany
Ralph Hruban, MD Director, GI / Liver Pathology Johns Hopkins University
Eileen O’Reilly, MD Associate Director for Clinical Research – Memorial Sloan-Kettering Cancer Center
Margaret Tempero, MD Chief, Medical Oncology University of California at San Francisco
PROPOSED: Every newly diagnosed person with pancreatic cancer (ductal adenocarcinoma of the pancreas) should receive genetic screening prior to beginning treatment – to test for germline genetic mutations in the homologous recombination DNA repair pathway, including genes such as BRCA1, BRCA2, PALB2, and others. These results, in from 12% to 17% of pancreatic cancer patients, suggest that treatment that includes DNA cross-linking agents such as platinum compounds or PARP inhibitors may be superior to standard best practices therapy.
OFFER: Color Genomics offers a 30-gene cancer panel for $224 (normally $249) when the Promotion Code “PANCREATIC” is entered at checkout (price will reduce upon entering this code). This is a physician-ordered saliva kit. Click Here for more information
RATIONALE: The age of precision medicine in pancreatic cancer is approaching … [MORE]
Our mission is to promote awareness, increase education, and further pancreatic cancer research, specifically research aimed at early diagnosis.
Pancreatic cancer is the 3rd leading cause of cancer-related death in the U.S. It is expected to become the 2nd leading cause of cancer-related death by the year 2020. Studies show that death rates for pancreatic cancer are increasing while for most other cancers they are declining.
It’s time to change these statistics!
Early diagnosis is key:
Survival increases dramatically if patients are diagnosed in time for surgery!
For medical information Click Here for our sister site Pancreatica.org
Choose a walk, run, or any other activity that you like and work to raise donations leading up to your Event! Simply set up your participation page and we will be in touch!
Already registered for your next Race? Dedicate your participation to Pancreatic Cancer. Simply set up your participation page and together we will work towards our shared mission!
Creating a Facebook Fundraiser is easy: Click the Link below and Facebook will take you through the steps! Dedicate your Birthday or another important date to honor a loved one.
Participate in #GivingTuesday for Pancreatic Cancer on December 3rd 2019!!
Click Here to Add a Calendar Reminder!
Amazon donates 0.5% of the price of your eligible AmazonSmile purchases to help fight pancreatic cancer!
AmazonSmile is the same Amazon you know. Same products, same prices, same service. Simply use our Link to start shopping!
Call 1-800-433-0464 for a free service that will place you in contact with a fellow survivor, or to volunteer to contact someone more recently diagnosed.
One of the observations that physicians often made when the standard of care treatment typically consisted of the chemotherapy drug agent of gemcitabine alone, was that many patients with pancreatic cancer (ductal adenocarcinoma of the pancreas) seemed to feel better after the initiation of treatment… More Here
HONOR A LOVED ONE
BY SHARING YOUR STORY
You can honor your loved one by sharing your story with us. Whether it’s your personal story, honoring a friend or relative’s journey, or why you support the cause, we want to hear from you!
In late March 2017, the French biotech firm Erytech presented results of a IIb clinical trial of eryaspase (trade name: GRASPA) which is the enzyme
The radiation component of adjuvant chemoradiation after surgery for ductal adenocarcinoma of the pancreas (pancreatic cancer) took a turn toward controversy beginning about year 2000
One of the observations that physicians often made when the standard of care treatment typically consisted of the chemotherapy drug agent of gemcitabine alone, was
Since the mid-1990s, teams affiliated with Dr. Daniel Von Hoff have ushered in two of the three key advances in the first-line treatment of advanced
